KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
Sponsor: Shanghai JMT-Bio Inc.
Listed as NCT05427383, this PHASE2/PHASE3 trial focuses on Stomach Cancer and remains actively recruiting participants. Sponsored by Shanghai JMT-Bio Inc., it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2022 — Jan 2024 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai JMT-Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .